The short version
- The American Cancer Society now advises routine prostate-specific antigen testing for men aged 50 to 69 at average risk, moving away from its prior non-universal stance.
- High-risk groups, including Black men and those with specific family histories, are advised to begin annual screening at age 45 due to elevated disease prevalence and earlier onset risks.
- Updated protocols emphasize active surveillance for low-risk diagnoses and require confirmatory imaging or biomarker tests before proceeding to invasive biopsies, aiming to reduce overtreatment harms.
The American Cancer Society has issued a substantial revision to its prostate cancer screening guidelines, recommending that all men undergo routine testing with the prostate-specific antigen blood test. This update represents a notable departure from the organization’s previous guidance, which was established in 2010 and did not advocate for universal screening. Instead, the earlier protocol encouraged shared decision-making between patients and physicians regarding whether to pursue testing. The new recommendations reflect an evolving understanding of how early detection can improve outcomes while managing the risks associated with overdiagnosis.
For men considered to be at average risk, the updated guidelines suggest receiving a PSA test every two years beginning at age 50 and continuing through age 69. This regular interval is designed to balance the benefits of detecting aggressive cancers early against the potential downsides of unnecessary medical interventions. The society notes that advances in case management have made it possible to avoid many of the harms previously associated with widespread screening, such as erectile dysfunction and urinary incontinence resulting from overtreatment.
Men identified as being at high risk are advised to start screening earlier and more frequently. Specifically, all Black men are recommended to begin annual testing at age 45, reflecting higher rates of prostate cancer incidence and mortality within this demographic. Non-Black men should also initiate yearly testing at age 45 if a close relative was diagnosed with prostate cancer before age 65 or if multiple relatives have had the disease. In cases where only one close relative was diagnosed at age 65 or older, non-Black men should start screening at 45 but may follow the biennial testing schedule rather than annual checks.
The guidelines provide specific instructions for men aged 70 to 74, advising them to consult with their healthcare providers about whether to continue screening based on individual health factors and life expectancy. For men aged 75 and older, routine screening is generally not recommended. This age-based stratification acknowledges that the benefits of early detection diminish as life expectancy decreases, while the risks of invasive procedures remain constant.
To mitigate the risk of false positives and unnecessary anxiety, the American Cancer Society has introduced guardrails into the testing process. Men are encouraged to be fully informed about both the potential benefits and risks before undergoing screening. If an initial PSA test returns a high result—defined as 3 ng/mL or higher for men under 70, and 6.5 ng/mL or higher for those 70 and older—the guidelines recommend repeating the test before taking any further action. This step helps confirm whether the elevated level is persistent or a temporary fluctuation.
If repeat testing continues to show high PSA levels, the next step involves more advanced diagnostic tools rather than immediate biopsy. Men should undergo either a prostate MRI or a validated biomarker test to better assess their risk profile. Biopsies are reserved for cases where there is a high suspicion of cancer, such as extremely elevated PSA results or concerning findings from imaging studies. This tiered approach aims to reduce the number of invasive procedures performed on men who do not have clinically significant disease.
For those diagnosed with prostate cancer, the guidelines emphasize active surveillance as the initial management strategy for low-risk cases. Many forms of prostate cancer grow slowly and may never cause harm during a patient’s lifetime. By monitoring these cases closely without immediate intervention, doctors can avoid the side effects associated with surgery or radiation therapy. This approach ensures that treatment is reserved for cancers that demonstrate aggressive behavior or potential to spread.
Prostate cancer remains one of the most common malignancies in men and is the second leading cause of cancer-related death in the United States. Estimates for 2026 indicate nearly 334,000 new diagnoses and over 36,300 deaths from the disease. The American Cancer Society argues that catching aggressive cancers early through simple blood tests opens the door to highly effective treatments that can protect long-term health. Meanwhile, lower-risk findings can be managed safely through careful observation.
The shift in guidance comes as other major health organizations review their own recommendations. The US Preventive Services Task Force, a federal panel responsible for evaluating preventive care evidence, is currently working on an update to its prostate cancer screening advice. However, the composition of this panel has recently changed, with new members reportedly having conflicts of interest and leadership shifts under Health Secretary Robert F. Kennedy Jr. These developments add complexity to the national conversation about preventive health measures.
Dr. Shanthi Sivendran, interim chief patient officer for the American Cancer Society, highlighted the dual benefit of the new approach in a statement. She noted that early detection allows for effective treatment of aggressive cancers while enabling safe management of lower-risk findings through active surveillance. The updated guidelines aim to provide clearer direction for both patients and providers, reducing uncertainty and promoting consistent care standards across different demographics.
Sources behind this briefing
Go to the original reporting
- Ars Technica↗In reversal, American Cancer Society urges prostate cancer tests for all men
